Submit a Review & Earn an Amazon Gift Card
You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!
Submit ReviewTASP 0433864 is a selective mGlu2 receptor positive allosteric modulator (EC50 values are 199 and 206 nM for human and rat receptors, respectively). Exhibits negligible activity against a range of neurotransmitter targets, except 5-HT2B and MAO-B (72 and 92% inhibition at 10 μM, respectively). Potentiates inhibitory effect of DCG IV (Cat. No. 0975) on excitatory postsynaptic potentials in hippocampal slices and ketamine- and methamphetamine-induced increases in locomotor activity in rats and mice.
TASP 0433864 is also offered as part of the Tocriscreen 2.0 Max. Find out more about compound libraries available from Tocris.
M. Wt | 329.39 |
Formula | C18H23N3O3 |
Storage | Store at +4°C |
Purity | ≥98% (HPLC) |
CAS Number | 1431980-60-7 |
PubChem ID | 124201847 |
InChI Key | IZYYTLCSQBACIP-AWEZNQCLSA-N |
Smiles | CC(C)(C)C1=CC=C(OC[C@@H]2CN3C(O2)=NC(C(N)=O)=C3C)C=C1 |
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
Solvent | Max Conc. mg/mL | Max Conc. mM | |
---|---|---|---|
Solubility | |||
DMSO | 32.94 | 100 | |
ethanol | 6.59 | 20 |
The following data is based on the product molecular weight 329.39. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
---|---|---|---|
1 mM | 3.04 mL | 15.18 mL | 30.36 mL |
5 mM | 0.61 mL | 3.04 mL | 6.07 mL |
10 mM | 0.3 mL | 1.52 mL | 3.04 mL |
50 mM | 0.06 mL | 0.3 mL | 0.61 mL |
References are publications that support the biological activity of the product.
Hiyoshi et al (2014) Neurophysiologic and antipsychotic profiles of TASP0433864, a novel positive allosteric modulator of metabotropic glutamate 2 receptor. J.Pharmacol.Exp.Ther. 351 642 PMID: 25277141
If you know of a relevant reference for TASP 0433864, please let us know.
View all Glutamate (Metabotropic) Group II Receptor Modulators
Keywords: TASP 0433864, TASP 0433864 supplier, TASP0433864, metabotropic, glutamate, receptors, 2, positive, allosteric, modulators, modulates, mGlu2, mGluR, selective, PAM, Glutamate, (Metabotropic), Group, II, Receptors, 5362, Tocris Bioscience
Citations are publications that use Tocris products.
Currently there are no citations for TASP 0433864. Do you know of a great paper that uses TASP 0433864 from Tocris? Please let us know.
There are currently no reviews for this product. Be the first to review TASP 0433864 and earn rewards!
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
The key feature of drug addiction is the inability to stop using a drug despite clear evidence of harm. This poster describes the brain circuits associated with addiction, and provides an overview of the main classes of addictive drugs and the neurotransmitter systems that they target.
Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.